Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine

Exclusion Criteria

• •Positive SARS-CoV-2 antigenic test
• •Positive SARS-CoV-2 polymerase chain reaction (PCR) results less than 48 hours old
• •History of infection by SARS-CoV-2 confirmed by antigenic test or PCR within 3 months prior to inclusion
• •Symptoms compatible with infection to SARS-CoV-2: sick or febrile participants (body temperature ≥ 38.0°C)
• •Pregnant or breastfeeding woman
• •Known chronic disease impacting the participant's immune response (uncured cancer, human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection)
• •Anti-coagulant treatment
• •Immunosuppressive treatment
• •Contraindication to the proposed vaccine (according to RCP)
• •Previously received at least one injection of a SARS-CoV-2 vaccine
• •Patient having received immunoglobulin or another blood product within 3 months prior to inclusion
• •A history of serious adverse vaccine reactions (anaphylaxis and associated symptoms such as rash, breathing difficulties, laryngeal edema, or a history of allergic reaction that may be exacerbated by a component of the SARS-CoV-2 vaccine)
• •Any condition that, in the opinion of the investigator, may adversely affect the well-being of the participant and interfere with the purpose of the study